ClinicalTrials.gg
CompletedNCT01684878Updated May 23, 2017Results posted

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

A Phase 3 interventional study of Gemcitabine (Chemotherapy) and Paclitaxel (Chemotherapy) in Ovarian Cancer, sponsored by Hoffmann-La Roche. Completed at 68 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-23.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing gemcitabine in Ovarian Neoplasms — none open to participants now, 2 under way, 1 of them phase 3. Gemcitabine · Ovarian Neoplasms.

Enrollment
5th of 34
208 · median 39
Started
2012
the only one that year
Phase 3
7 of 40
none open now
Registered
36th of 40
by date

Among the 40 studies testing gemcitabine in Ovarian Neoplasms, this one is the 5th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2012, is one of 7 in phase 3, and was the 36th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 40 studies testing gemcitabine in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing gemcitabine in Ovarian Neoplasms as a file.
02

Study summary

This two-part, multicenter study will evaluate the safety, tolerability and efficacy of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer. In the non-randomized Part 1 safety run-in, participants will receive pertuzumab plus either topotecan or paclitaxel. In the randomized, double-blind Part 2 of the study, participants will receive either pertuzumab or placebo in combination with chemotherapy (topotecan, paclitaxel, or gemcitabine).

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed epithelial ovarian, primary peritoneal, and/or fallopian tube cancer that is platinum-resistant or
  • Low Human epidermal growth factor receptor (HER) 3 messenger ribonucleic acid (mRNA) expression
  • At least one measurable and/or non- according to (RECIST) version (V) 1.1
  • (ECOG) performance status 0 to 2
  • (LVEF) greater than or equal to (>/=) 50 percent (%)
  • Negative serum pregnancy test in women of
  • Women of childbearing potential must agree to use effective as defined by protocol during and for at least 6 months post study treatment

Exclusion criteria

Exclusion Criteria:

  • Non-epithelial tumors
  • Ovarian tumors with low malignant potential (borderline tumors)
  • History of other of prognostic relevance within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma, or tumors with a negligible risk for or death, such as adequately controlled basal-cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ of the breast
  • Previous treatment with more than 2 chemotherapy regimens
  • Any prior radiotherapy to the pelvis or abdomen
  • History or evidence on physical/neurological examination of central nervous system disease unrelated to cancer (uncontrolled seizures), unless adequately treated with standard medical therapy
  • Pre-existing peripheral neuropathy >/= common toxicity criteria (CTC) grade 2 (applicable for paclitaxel cohort only)
  • Inadequate organ function
  • Uncontrolled hypertension or cardiovascular disease
  • Current known infection with (HIV) or active infection with virus (HBV), or virus (HCV)
  • Current chronic daily treatment with (>/= 10 mg per day of methylprednisolone or equivalent), excluding inhaled steroids
  • History of receiving any treatment within 28 days prior to first study drug administration
  • For Part 2 of the trial: prior enrollment into Part 1 of the trial
  • Concurrent participation in any therapeutic clinical trial
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    Part 1: Pertuzumab + Topotecan

    Participants received pertuzumab and topotecan in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.

    Drug: Paclitaxel (Chemotherapy) · Drug: Pertuzumab · Drug: Topotecan (Chemotherapy)

  • Experimental
    Part 1: Pertuzumab + Paclitaxel

    Participants received pertuzumab and paclitaxel in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.

    Drug: Paclitaxel (Chemotherapy) · Drug: Pertuzumab · Drug: Placebo

  • Experimental
    Part 2: Pertuzumab+Chemotherapy

    Participants received pertuzumab and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.

    Drug: Gemcitabine (Chemotherapy) · Drug: Paclitaxel (Chemotherapy) · Drug: Pertuzumab · Drug: Topotecan (Chemotherapy)

  • Placebo comparator
    Part 2: Placebo+Chemotherapy

    Participants received pertuzumab matching placebo and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.

    Drug: Gemcitabine (Chemotherapy) · Drug: Paclitaxel (Chemotherapy) · Drug: Placebo · Drug: Topotecan (Chemotherapy)

Interventions

  • Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.

  • Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.

  • Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.

  • DrugPlacebo

    Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.

  • Participants administered topotecan at a dosage of 1.25 mg/m\^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Part 1: Percentage of Participants With Adverse Events (AEs)

    An AE can be any unfavorable and unintended sign (including an abnormality laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Approximately 28 months (assessed at screening, baseline until 28 days after the last dose of study treatment)

  2. Part 2: Progression Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Including Malignant Bowel Obstruction (MBO)

    PFS (IRC-Assessed) was defined as the time from randomization into Part 2 of the trial until progressive disease (PD), MBO or death from any cause, whichever occurred first per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.

    Time frame: Approximately 44 months (assessed at screening and every 9 weeks from randomization until disease progression)

Secondary outcomes

  1. Part 1- Objective Response Rate (ORR)

    ORR was defined as the number of participants with best overall response (BOR) of complete response (CR) or partial response (PR) recorded from the start of treatment, until the end of treatment. BOR documented as confirmed CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeter (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Approximately 28 months (assessed at baseline and every 9 weeks from randomization until disease progression)

  2. Part 2- Objective Response Rate (ORR)

    ORR was defined as the number of participants with BOR of CR or PR recorded from the start of treatment, until the end of treatment. BOR documented as confirmed CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeter (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Approximately 44 months (assessed at screening and every 9 weeks from randomization until disease progression)

  3. Part 1: PFS Assessed by the Investigator

    PFS as assessed by Investigator was defined as the time from first dose of pertuzumab or chemotherapy in Part 1 of the trial, until disease progression according to RECIST version 1.1, symptomatic deterioration or death from any cause, whichever occurs first. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions. Participants were censored at the last tumor assessment. Participants who have no tumor assessments after baseline and who were still alive will be censored at 1 day.

    Time frame: Approximately 28 months (assessed at screening and every 9 weeks from randomization until disease progression)

  4. Part 2: Progression-free Survival (PFS) Assessed by the Investigator

    PFS (Investigator-assessed) is defined as the time from randomization, until disease progression according to RECIST v1.1 including death or MBO, whichever occurs first. Censoring is based on the last tumor assessment. If no tumor assessment post baseline, then censoring is at day 1. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.

    Time frame: Approximately 44 months (assessed at screening and every 9 weeks from randomization until disease progression)

  5. Part 2: European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire (QLQ) of Core 30 (C30) Score

    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores averaged, transformed to 0-100 scale; for functional scores, a higher score represents a better level of functioning. For symptom scores, a higher score represents a more severe level of symptoms. For the global health status scores, a higher score represents a better quality of life.

    Time frame: Baseline (assessed at baseline and every 9 weeks from randomization until disease progression)

  6. Part 2: Percentage of Participants With Adverse Events (AEs)

    An AE can be any unfavorable and unintended sign (including an abnormality laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Approximately 28 months (assessed at screening, baseline until 28 days after the last dose of study treatment)

  7. Part 2: Overall Survival

    Overall survival was defined as the time from randomization into Part 2 of the trial until death from any cause

    Time frame: Approximately 44 months (assessed at screening and every 9 weeks from randomization until disease progression)

07

Results

Posted Nov 23, 2016

Participant flow

Part 1: Safety Run in Phase
Participant flow — Part 1: Safety Run in Phase
MilestonePart 1: Pertuzumab + TopotecanPart 1: Pertuzumab + PaclitaxelPart 2: Pertuzumab+ChemotherapyPart 2: Placebo+Chemotherapy
Started222800
Completed6500
Not completed162300
Withdrew: Participants withdrawn consent1100
Withdrew: Death152000
Withdrew: Lost to follow-up0200
Part 2: Randomized Phase
Participant flow — Part 2: Randomized Phase
MilestonePart 1: Pertuzumab + TopotecanPart 1: Pertuzumab + PaclitaxelPart 2: Pertuzumab+ChemotherapyPart 2: Placebo+Chemotherapy
Started007878
Participants randomized but not treated0012
Participants mis-randomized0020
Completed0000
Not completed007878
Withdrew: Participant withdrew consent0012
Withdrew: Lost to follow-up0020
Withdrew: Death006268
Withdrew: Alive at data-cut00137
Withdrew: Participant noncompliance0001

Outcome measures

PrimaryPart 1: Percentage of Participants With Adverse Events (AEs)

An AE can be any unfavorable and unintended sign (including an abnormality laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Approximately 28 months (assessed at screening, baseline until 28 days after the last dose of study treatment)
Reported as:
Number · percentage of participants
Part 1: Percentage of Participants With Adverse Events (AEs)
percentage of participantsPart 1: Pertuzumab + TopotecanPart 1: Pertuzumab + Paclitaxel
Part 1: Percentage of Participants With Adverse Events (AEs)95.5100.0
PrimaryPart 2: Progression Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Including Malignant Bowel Obstruction (MBO)

PFS (IRC-Assessed) was defined as the time from randomization into Part 2 of the trial until progressive disease (PD), MBO or death from any cause, whichever occurred first per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.

Time frame:
Approximately 44 months (assessed at screening and every 9 weeks from randomization until disease progression)
Reported as:
Median · months
Part 2: Progression Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Including Malignant Bowel Obstruction (MBO)
monthsPart 2: Pertuzumab+ChemotherapyPart 2: Placebo+Chemotherapy
Part 2: Progression Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Including Malignant Bowel Obstruction (MBO)4.27 (3.65 to 6.11)2.74 (2.14 to 4.73)
Statistical analysis
  • Part 2: Pertuzumab+Chemotherapy vs Part 2: Placebo+Chemotherapy · 2 sided log-rank · p = 0.4983 · Hazard ratio (stratified): 0.88 · 95% CI 0.62 to 1.27
SecondaryPart 1- Objective Response Rate (ORR)

ORR was defined as the number of participants with best overall response (BOR) of complete response (CR) or partial response (PR) recorded from the start of treatment, until the end of treatment. BOR documented as confirmed CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeter (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Approximately 28 months (assessed at baseline and every 9 weeks from randomization until disease progression)
Reported as:
Number · percentage of participants
Part 1- Objective Response Rate (ORR)
percentage of participantsPart 1: Pertuzumab + TopotecanPart 1: Pertuzumab + Paclitaxel
Part 1- Objective Response Rate (ORR)14.325.0
SecondaryPart 2- Objective Response Rate (ORR)

ORR was defined as the number of participants with BOR of CR or PR recorded from the start of treatment, until the end of treatment. BOR documented as confirmed CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeter (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Approximately 44 months (assessed at screening and every 9 weeks from randomization until disease progression)
Reported as:
Number · percentage of participants
Part 2- Objective Response Rate (ORR)
percentage of participantsPart 2: Pertuzumab+ChemotherapyPart 2: Placebo+Chemotherapy
Part 2- Objective Response Rate (ORR)14.8 (7.0 to 26.2)8.7 (3.3 to 18.0)
Statistical analysis
  • Part 2: Pertuzumab+Chemotherapy vs Part 2: Placebo+Chemotherapy · Fisher Exact · p = 0.4102 · Difference in response rate: 6.06 · 95% CI 6.0 to 18.3Approximate 95% CI for difference of 2 rates using Hauck-Anderson method.
SecondaryPart 1: PFS Assessed by the Investigator

PFS as assessed by Investigator was defined as the time from first dose of pertuzumab or chemotherapy in Part 1 of the trial, until disease progression according to RECIST version 1.1, symptomatic deterioration or death from any cause, whichever occurs first. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions. Participants were censored at the last tumor assessment. Participants who have no tumor assessments after baseline and who were still alive will be censored at 1 day.

Time frame:
Approximately 28 months (assessed at screening and every 9 weeks from randomization until disease progression)
Reported as:
Median · months
Part 1: PFS Assessed by the Investigator
monthsPart 1: Pertuzumab + TopotecanPart 1: Pertuzumab + Paclitaxel
Part 1: PFS Assessed by the Investigator4.07 (1.94 to 6.08)4.24 (3.45 to 6.01)
SecondaryPart 2: Progression-free Survival (PFS) Assessed by the Investigator

PFS (Investigator-assessed) is defined as the time from randomization, until disease progression according to RECIST v1.1 including death or MBO, whichever occurs first. Censoring is based on the last tumor assessment. If no tumor assessment post baseline, then censoring is at day 1. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.

Time frame:
Approximately 44 months (assessed at screening and every 9 weeks from randomization until disease progression)
Reported as:
Median · months
Part 2: Progression-free Survival (PFS) Assessed by the Investigator
monthsPart 2: Pertuzumab+ChemotherapyPart 2: Placebo+Chemotherapy
Part 2: Progression-free Survival (PFS) Assessed by the Investigator4.22 (3.25 to 5.22)3.94 (2.63 to 4.30)
SecondaryPart 2: European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire (QLQ) of Core 30 (C30) Score

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores averaged, transformed to 0-100 scale; for functional scores, a higher score represents a better level of functioning. For symptom scores, a higher score represents a more severe level of symptoms. For the global health status scores, a higher score represents a better quality of life.

Time frame:
Baseline (assessed at baseline and every 9 weeks from randomization until disease progression)
Reported as:
Mean · units on a scale
Part 2: European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire (QLQ) of Core 30 (C30) Score
units on a scalePart 2: Pertuzumab+ChemotherapyPart 2: Placebo+Chemotherapy
Functional Scales: Physical (n=71, 74)71.1 ± 22.7774.9 ± 20.85
Functional Scales: Role (n=70, 73)68.6 ± 33.1669.4 ± 32.40
Functional Scales: Emotional (n=71, 73)59.5 ± 24.0365.9 ± 23.42
Functional Scales: Cognitive (n=71, 73)81.2 ± 25.3484.9 ± 20.25
Functional Scales: Social (n=71, 73)70.7 ± 30.0168.3 ± 29.81
Symptomatic Scales: Fatigue (n=71, 74)41.2 ± 28.7538.4 ± 27.77
Symptomatic Scales: Nausea and vomiting (n=72, 74)10.4 ± 15.6812.4 ± 20.47
Symptomatic Scales: Pain (n=72, 74)35.2 ± 31.3431.1 ± 29.24
Symptomatic Scales: Dyspnoea (n=68, 73)22.5 ± 28.4721.5 ± 27.98
Symptomatic Scales: Insomnia (n=69, 74)35.3 ± 31.2531.5 ± 31.16
Symptomatic Scales: Appetite loss (n=71, 73)24.9 ± 30.1921.0 ± 26.36
Symptomatic Scales: Constipation (n=69, 72)25.6 ± 32.4126.4 ± 32.59
Symptomatic Scales: Diarrhoea (n=69, 72)14.5 ± 26.4914.4 ± 22.26
Symptomatic Scales:Financial difficulties(n=70,7217.6 ± 28.7813.4 ± 22.83
Global health status / QoL scale (n=71, 72)54.1 ± 24.9961.1 ± 22.29
SecondaryPart 2: Percentage of Participants With Adverse Events (AEs)

An AE can be any unfavorable and unintended sign (including an abnormality laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Approximately 28 months (assessed at screening, baseline until 28 days after the last dose of study treatment)
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants With Adverse Events (AEs)
percentage of participantsPart 2: Pertuzumab+ChemotherapyPart 2: Placebo+Chemotherapy
Part 2: Percentage of Participants With Adverse Events (AEs)98.7100
SecondaryPart 2: Overall Survival

Overall survival was defined as the time from randomization into Part 2 of the trial until death from any cause

Time frame:
Approximately 44 months (assessed at screening and every 9 weeks from randomization until disease progression)
Reported as:
Median · months
Part 2: Overall Survival
monthsPart 2: Pertuzumab+ChemotherapyPart 2: Placebo+Chemotherapy
Part 2: Overall Survival10.18 (6.67 to 15.24)8.36 (6.14 to 11.99)
Statistical analysis
  • Part 2: Pertuzumab+Chemotherapy vs Part 2: Placebo+Chemotherapy · 2 sided log-rank · p = 0.5960 · Hazard ratio (stratified): 0.90 · 95% CI 0.61 to 1.32A hazard ratio \< 1 favored the Pertuzumab + Chemotherapy treatment group

Adverse events

Collected over Approximately 28 months (assessed at screening, baseline until 28 days after the last dose of study treatment). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Pertuzumab + Topotecan—9/22 (40.9%)21/22 (95.5%)
Part 1: Pertuzumab + Paclitaxel—11/28 (39.3%)27/28 (96.4%)
Part 2: Pertuzumab+Chemotherapy—29/77 (37.7%)72/77 (93.5%)
Part 2: Placebo+Chemotherapy—33/76 (43.4%)75/76 (98.7%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventPart 1: Pertuzumab + TopotecanPart 1: Pertuzumab + PaclitaxelPart 2: Pertuzumab+ChemotherapyPart 2: Placebo+Chemotherapy
NeutropeniaBlood and lymphatic system disorders2/220/280/770/76
Intestinal ObstructionGastrointestinal disorders0/222/280/774/76
AnaemiaBlood and lymphatic system disorders0/222/281/772/76
PyrexiaGeneral disorders0/222/281/772/76
DiarrhoeaGastrointestinal disorders1/220/284/770/76
Abdominal PainGastrointestinal disorders1/220/282/772/76
NauseaGastrointestinal disorders1/220/281/771/76
SubileusGastrointestinal disorders1/220/283/771/76
VomitingGastrointestinal disorders1/220/283/772/76
Febrile NeutropeniaBlood and lymphatic system disorders1/220/282/771/76
Most frequent other events
Showing 10 of 79
Most frequent other events
EventPart 1: Pertuzumab + TopotecanPart 1: Pertuzumab + PaclitaxelPart 2: Pertuzumab+ChemotherapyPart 2: Placebo+Chemotherapy
DiarrhoeaGastrointestinal disorders14/2222/2850/7723/76
AnaemiaBlood and lymphatic system disorders15/2210/2828/7732/76
AstheniaGeneral disorders14/228/2832/7724/76
VomitingGastrointestinal disorders13/225/2819/7723/76
NauseaGastrointestinal disorders11/2210/2831/7734/76
Decreased AppetiteMetabolism and nutrition disorders8/225/2813/7717/76
FatigueGeneral disorders5/2210/2821/7724/76
AlopeciaSkin and subcutaneous tissue disorders7/2210/2815/7721/76
Mucosal InflammationGeneral disorders7/222/2811/776/76
NeutropeniaBlood and lymphatic system disorders5/223/2823/7721/76

Baseline characteristics

Part 1: all participants enrolled and treated in Part 1 of the study ('as treated' analysis) and Part 2: intent-to-treat (ITT) population was defined as all randomized participants in the group to which they were randomly assigned ('as randomized' analysis).

Age, Customized
Age, Customized(participants)Part 1: Pertuzumab + TopotecanPart 1: Pertuzumab + PaclitaxelPart 2: Pertuzumab+ChemotherapyPart 2: Placebo+ChemotherapyTotal
Less than or equal to (≤)65 years15174044116
Greater than (>)65 years711383490
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Pertuzumab + TopotecanPart 1: Pertuzumab + PaclitaxelPart 2: Pertuzumab+ChemotherapyPart 2: Placebo+ChemotherapyTotal
Female22287878206
Male00000
08

Study locations

68 sites
  • Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie
    Innsbruck, 6020, Austria
  • Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie
    Wien, 1090, Austria
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Herlev Hospital; Onkologisk afdeling
    Herlev, 2730, Denmark
  • Rigshospitalet, Onkologisk Klinik
    København Ø, 2100, Denmark
  • Institut Bergonie; Oncologie
    Bordeaux, 33076, France
  • Centre Francois Baclesse; Oncologie
    Caen, 14076, France
  • Centre Georges Francois Leclerc; Oncologie 3
    Dijon, 21079, France
  • CRLCC Val dAurelle Paul Lam
    Montpellier cedex 5, 34298, France
  • Hopital Tenon; Oncologie Radiotherapie
    Paris, 75970, France
  • Ch Lyon Sud; Chir Onc Gyne Sct Jules Courmont
    Pierre Benite, 69310, France
  • Clinique Armoricaine Radiologie; Hopital de Jour
    Plerin, 22190, France
  • Ico Rene Gauducheau; Oncologie
    Saint Herblain, 44805, France
  • Centre Alexis Vautrin; Oncologie Medicale
    Vandoeuvre Les Nancy, 54511, France
  • Institut Gustave Roussy; Oncologie Medicale
    Villejuif, 94800, France
  • Universitätsklinikum "Carl Gustav Carus"; Frauenheilkunde und Geburtshilfe
    Dresden, 01307, Germany
  • Evangelischen Krankenhauses Düsseldorf; Frauenklinik
    Düsseldorf, 40217, Germany
  • Universitätsklinikum Essen; Zentrum Für Frauenheilkunde
    Essen, 45122, Germany
  • Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie
    Essen, 45136, Germany
  • Universitätsklinikum Freiburg; Frauenklinik
    Freiburg, 79106, Germany
  • Universitätsklinikum Greifswald; Klinik für Frauenheilkunde und Brustzentrum
    Greifswald, 17475, Germany
  • Universitätsklinikum Hamburg-Eppendorf (UKE); Klinik und Poliklinik für Gynäkologie
    Hamburg, 20246, Germany
  • Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding
    Hannover, 30177, Germany
  • Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg
    Heidelberg, 69120, Germany
  • UNI-Klinikum Campus Kiel Klinik f.Gynäkologie u.Geburtshilfe
    Kiel, 24105, Germany
  • St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe
    Koeln, 50935, Germany
  • Klinikum Konstanz, Frauenklinik
    Konstanz, 78464, Germany
  • Klinikum rechts der Isar der TU München; Frauenklinik & Poliklinik
    München, 81675, Germany
  • Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe
    Offenbach, 63069, Germany
  • Hämatologisch/Onkologische Praxis Dr. Herbrick - Zipp/Prof. Dr. Decker, Studienzentrum
    Ravensburg, 88212, Germany
  • Universitätsfrauen- und Poliklinik am Klinikum Suedstadt
    Rostock, 18059, Germany
  • Universitätsklinik Tübingen; Frauenklinik
    Tübingen, 72076, Germany
  • Universitätsklinikum Ulm Am Michelsberg; Frauenklinik
    Ulm, 89075, Germany
  • HELIOS Dr. Horst Schmidt Kliniken Wiesbaden; Klinik für Gynäkologie und gynäkologische Onkologie
    Wiesbaden, 65199, Germany
  • Istituto Tumori Napoli;Unità Operativa Oncologia Medica Uro-Ginecologica
    Napoli, Campania 80131, Italy
  • Istituto Regina Elena; Oncologia Medica A
    Roma, Lazio 00168, Italy
  • Ente Ospedaliero Ospedali Galliera; S.C. Oncologia Medica
    Genova, Liguria 16128, Italy
  • A.O.Spedali Civili; Ostetricia e Ginecologia
    Brescia, Lombardia 25123, Italy
  • Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica
    Milano, Lombardia 20133, Italy
  • Istituto Europeo Di Oncologia
    Milano, Lombardia 20141, Italy
  • A.O.U Pisana; Dipartimento di Ginecologia Oncologica
    Pisa, Toscana 56126, Italy
  • Antoni van Leeuwenhoek Ziekenhuis
    Amsterdam, 1066 CX, Netherlands
  • Academ Ziekenhuis Groningen; Medical Oncology
    Groningen, 9713 GZ, Netherlands
  • Academisch Ziekenhuis Leiden; Clinical Oncology
    Leiden, 2333 ZA, Netherlands
  • UMC St Radboud
    Nijmegen, 6525 GA, Netherlands
  • The Norvegian Radium Hospital Montebello; Dept of Oncology
    Oslo, 0379, Norway
  • Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
    Sabadell, Barcelona 08208, Spain
  • Hospital Son Llatzer; Servicio de Oncologia
    Palma de Mallorca, Islas Baleares 07198, Spain
  • Hospital Univ Vall d'Hebron; Servicio de Oncologia
    Barcelona, 08035, Spain
  • Hospital Clínic i Provincial; Servicio de Hematología y Oncología
    Barcelona, 08036, Spain
  • Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
    Barcelona, 08041, Spain
  • Hospital Duran i Reynals; Oncologia
    Barcelona, 08907, Spain
  • Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
    Barcelona, 08916, Spain
  • Hospital Universitario Reina Sofia; Servicio de Oncologia
    Cordoba, 14004, Spain
  • Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia
    Girona, 17007, Spain
  • Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia
    Lerida, 25198, Spain
  • Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
    Madrid, 28007, Spain
  • Centro Oncologico MD Anderson Internacional; Servicio de Oncologia
    Madrid, 28033, Spain
  • Hospital Universitario 12 de Octubre; Servicio de Oncologia
    Madrid, 28041, Spain
  • Hospital Universitario La Paz; Servicio de Oncologia
    Madrid, 28046, Spain
  • Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica
    Madrid, 28050, Spain
  • Hospital Regional Universitario Carlos Haya; Servicio de Oncologia
    Malaga, 29010, Spain
  • Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia
    Murcia, 30120, Spain
  • Instituto Valenciano Oncologia; Oncologia Medica
    Valencia, 46009, Spain
  • Hospital Universitario la Fe; Servicio de Oncologia
    Valencia, 46026, Spain
  • Hospital Universitario Miguel Servet; Servicio Oncologia
    Zaragoza, 50009, Spain
  • Universitetssjukhuset; Onkologkliniken
    Linkoeping, 58185, Sweden
  • Skånes University Hospital, Skånes Department of Onclology
    Lund, 22185, Sweden
09

References and documents

Publications

  • Lorusso D, Hilpert F, Gonzalez Martin A, Rau J, Ottevanger P, Greimel E, Luck HJ, Selle F, Colombo N, Kroep JR, Mirza MR, Berger R, Pardo B, Grischke EM, Berton-Rigaud D, Martinez-Garcia J, Vergote I, Redondo A, Cardona A, Bastiere-Truchot L, du Bois A, Kurzeder C; PENELOPE trial investigators. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2019 Sep;29(7):1141-1147. doi: 10.1136/ijgc-2019-000370. Epub 2019 Aug 15. PubMed 31420414 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Jan 2015, 27 months.

Results were first posted in Nov 2016, 1 year 9 months after primary completion.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 27 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2012
First posted
Sep 13, 2012
StartActual
Oct 22, 2012
Primary completionActual
Jan 30, 2015
CompletionActual
Apr 28, 2016
Results first posted
Nov 23, 2016
Last update
May 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01684878
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 13, 2012
Start date
Oct 22, 2012
Primary completion
Jan 30, 2015
Completion
Apr 28, 2016
Results posted
Nov 23, 2016
Last update
May 23, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Pertuzumab · Topotecan

Start the discussion